Drug Trial Radar · NCT07035379
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL
Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Sep 1, 2025
Primary completion
Sep 1, 2026
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Zhejiang Teruisi Pharmaceutical Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the "3 + 3" rule. Patients with previously untreated patients with CD20-positive DLBCL were selected to evaluate the safety, tolerance (DLT, MTD), pharmacokinetics, and anti-tumor activity of TRS005 in combination with standard doses of cyclophosphamide, doxorubicin, and prednisone(T-CHP) by intravenous drip every 3 weeks.
Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
TRS005Drug
TRS005 will be administered at a starting dose of 0.8mg/kg IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles (up to 8).
CyclophosphamideDrug
Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
DoxorubicinDrug
Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
PrednisoloneDrug
Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I: Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)Time frame: Cycle 1 Day 1 (C1D1) to Cycle 1 Day 21 (C1D21)
- Part I and II: Adverse EventsTime frame: Day 1 up to approximately 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences, Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.